This position is located in the Office of Technology Transitions and reports directly to the Director, Office of Technology Transitions. If selected for this position, you will manage the OTT staff, as the advisor to the Director, and provide continuity between administrations. The Deputy Director will be a senior level staff serving as a point of contact for entities like the Laboratory Operations (LOB), Laboratory Policy Council (LPC), and Secretary's External Advisory Board (SEAB). The Deputy Director will manage the intra-agency tech Transfer Policy Board (TTPB). The Deputy Director will serves as an integral part of the Office of Technology Transitions, overseeing the day-today operations of the Office, continuously seeking efficiencies by providing oversight and coordination. The Deputy Director will develop and manage fit-for purpose oversight processed and procedures for technology transfer and reporting systems, including intellectual property, across the DOE enterprise. The Deputy Director will lead the development of annual OTT deliverables, working with appropriate DOE programmatic elements. The Deputy Director will lead OTT staff to ensure delivery of state of the art data management processes and solutions supporting effective technology transitions and outreach to the private sector. The Deputy Director will lead interactions needed with the Executive Office of the White House, the Office of Management and Budget (OMB), the General Services Administration (GSA), Congressional Committees and Subcommittees, State Officials, the non-profit sector, and other non-commercial entities to ensure DOE technology transitions polices and priorities are appropriately linked with related initiatives, and to improve existing, or develop new, processes and procedures for supporting technology transfer solutions.

The Obama administration has launched a ‘moonshot’ initiative to cure cancer that will involve increasing resources – both private and public – to fight cancer and break down walls between disciplines in the oncology arena. The effort will be led by vice president Joe Biden, who lost his son to brain cancer last year, President Obama announced during his final State of the Union speech. Biden worked with Congress last month to provide the US National Institutes of Health with its strongest budget in over a decade, Obama noted. ‘Let’s make America the country that cures cancer once and for all,’ he added.

Washington-area businesses raised more venture capital in the fourth quarter than they had in any quarter since 2001 — largely due to a few large deals.

The surge is not likely to be repeated soon given the recent stock market turmoil. Indeed, venture funding nationally declined during the period.

The TCM Industry Awards Celebration is the only awards ceremony that honors the best in Maryland’s technology and life science communities and is one of Maryland’s largest and most prestigious award ceremonies.

Awards go to those who develop the treatments, design the systems, and teach the children. It’s a celebration of great minds and the companies that believe in the future, and is attended by over 800 executives from the technology and life science industries, drawing a significant amount of local and national publicity.

What's the difference between a relatively flat economy and a vibrant and diversified region with high job and economic growth? Working together. That was the pitch Thursday morning as economist Steve Fuller unveiled the findings after months of research for a project dubbed “ The Roadmap for the Washington Region’s Economic Future.”

You’ve heard of 3-D printers creating architectural models, airplane parts and even prosthetic limbs. But bones? Warren Grayson, an assistant professor of biomedical engineering at Johns Hopkins University, says it’s possible and not so far off in the future.

TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.

Kenneth Clark remembers the last time new investors moved into biotech. They came in the late 1980s.

They left in the early ’90s.

GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies in Toronto with an investment of CAD $40M from GE and FedDev Ontario. The centre is being established to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. CCRM and GE will welcome partners from pharma, biotech and cell therapy companies to bring this initiative to life. 

It wasn't expected to be a major State of the Union address—a final speech from a president in his last term, recounting achievements and expressing hope for the future. And then Obama made some news: "Let’s make America the country that cures cancer once and for all." And to lead the administration's effort, the president picked VP Joe Biden, who recently lost his son Beau to cancer, and who has said that finding a cure is one of his major life goals

ATCC, the premier global biological materials resource and standards organization, announces today that it licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard. ATCC plans to use the gene editing technology to develop a portfolio of new products and services to support basic and translational research.

Ligand Pharmaceuticals  enters into a global license agreement with Emergent BioSolutions under which Emergent will use Ligand's OmniRat, OmniMouse and OmniFlic technologies to discover fully human mono- and bispecific antibodies.

AUTM today released its highly regarded annual U.S. Licensing Activity Survey report for FY2014. Along with real world and human impact stories about technology transfer’s ability to improve lives and boost economies, the report analyzes licensing activities at U.S. universities, hospitals and research institutions, with data such as the following:

In a partnership announced today, MedImmune, AstraZeneca’s global biologics and development arm, and the University of California, San Francisco will initiate further exploration of disease biology, specifically delving into core underlying mechanisms in microbiome and regenerative medicine. With an emphasis on basic research and translational sciences, the organizations’ work will include working toward identifying biomarkers and understanding disease progression and the effects of biomarkers on clinical trial outcomes.

NEW YORK (GenomeWeb) – Qiagen said yesterday that it has inked a master collaboration for companion diagnostics codevelopment with Array BioPharma, the 15^th pharma agreement of this type.

The way Health and Human Services Chief Technology Officer Susannah Fox sees it, the U.S. government totally missed the Internet boom and has been trying to catch up with ever since.

“I would say gently that the government was caught flat footed when the Internet came about,” she said

Advanced Accelerator Applications S.A. (NASDAQ: AAAP) announced an exclusive license agreement with Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-SR6, a receptor ligand of Prostate-Specific Membrane Antigen (PSMA) for clinical therapeutic and diagnostic purposes. AAA will focus on developing this treatment and its companion diagnostic for prostate cancer through novel molecular nuclear medicine techniques similar to those implemented for the development of Lutathera and Somakit. Prostate cancer affects nearly 1 in 7 men during their lifetime worldwide.

AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics™ for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.

Leading global start up accelerator Dreamit today announced that it has renewed its partnerships with industry leaders Independence Blue Cross (Independence) and Penn Medicine to advance entrepreneurship and innovation in health care. The continued support follows significant upgrades to the Dreamit Health program announced earlier this year. The new model includes key changes designed to appeal to a broader range of entrepreneurs, including a no-cash/no-equity offer to draw later-stage companies and serial entrepreneurs who would not typically consider an accelerator program.

Biological researchers should be able to share datasets the same way they share published scientific articles — at least, that’s what the National Institutes of Health is trying to ensure with a new project. 

NIH is building a virtual space called “the Commons,” where researchers can one day do just that: share data, software and any other virtual tools or research processes in a way that’s “Findable, Accessible, Interoperable and Reusable,” or “FAIR.”

Rewards for creative people; investments in new ideas that challenge the power of the Pope and sovereign rulers, that give impetus to science and give birth to the new class of merchant nobles creators of wealth with their businesses: this the Renaissance.

The American Medical Association has invested $15 million to become founding partner of Health2047, a high-tech incubator that will explore innovative solutions to some of the biggest challenges facing the nation's 1.1 million physicians and their patients.

Sucampo Pharmaceuticals (NASDAQ:SCMP) has acquired an option to commercialize a drug candidate aimed at preventing colon cancer among a high-risk group of patients in a deal worth up to $190 million. Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it's left untreated.

Thursday January 21, 2016 from 5:00 PM to 7:00 PM EST

Johns Hopkins Montgomery County Campus is also a site for the popular Osher Lifelong Learning Institute. Geared toward retirees, these non-credit classes cover topics including opera, literature, history, politics and more.

The campus is home to approximately 35 research companies and entrepreneurs. Scientists on campus are studying cervical cancer, Alzheimer's disease, cell therapy, proteins and other health issues. Other companies focus on technology, medical devices and consulting services. The Rockville Science Center's administrative offices are located here. Start-up companies, second-stage businesses and more established companies are welcome.

Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).

Ah. Another January, another J.P. Morgan Healthcare Conference — where this year’s biggest biopharma deals are just a cocktail and a handshake away. As swaths of C-suite execs descend upon San Francisco, here’s an overview of some of the ideas we expect to see in motion at the conference (cattle yard) this week:

We’re one step closer to open-source collaboration in the life sciences – and could come a hell of a lot closer to completely revolutionizing cancer treatment – thanks to a promising new alliance formed by the top brass in biopharma.

Meant to accelerate the potential of immunotherapy in treating cancer, The National Immunotherapy Coalition has just been launched by leaders from Amgen, Celgene, GlaxoSmithKline, Merck, and NantWorks – along with Independence Blue Cross and many others. Here’s why:

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a favorable private letter ruling from the Internal Revenue Service related to the planned spin-off of its biosciences business. Subject to its terms, the ruling confirms that certain aspects of the planned transaction, including those related to the qualification of the business as an active trade or business, will not preclude the spin-off from qualifying as tax-free to Emergent and its stockholders.

Our region’s business community has a self-esteem problem. We nod shamefully when we are told we depend on government dollars for success.

Wrong.

The world’s largest DNA sequencing company says it will form a new company to develop blood tests that cost $1,000 or less and can detect many types of cancer before symptoms arise.

Illumina, based in San Diego, said its blood tests should reach the market by 2019, and would be offered through doctors’ offices or possibly a network of testing centers.

Deloitte today announced a strategic alliance agreement with AT&T aimed at accelerating the adoption of smart city technology across U.S. cities. The telco and global management consultancy, along with several other hand-picked alliance members, strive to enhance livability and improve the efficiencies of local governments through optimal use of today's technology.

Six startups have been selected for the Emerging Technology Centers’ AccelerateBaltimore program and one will receive an extra investment of $100,000. Now in its fifth year, AccelerateBaltimore is a four month program that aims to help promising startup companies come closer to bringing their products or services to market. The program is backed by $170,000 from the Abell Foundation. The money largely goes toward the $25,000 award given to each participating company.

OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.

Guy Marcus, a 24-year-old Ph.D. candidate in physics at the Johns Hopkins University, is one of 30 young scientists named to Forbes magazine's annual "30 Under 30" list.

As usual, we bring you the top five entries from our most recent list. This week, it's the top venture capital recipients in Maryland, based on funding received between the first and third quarters of 2015.